IOVA250516P2000
- 0.20
- +0.03+17.65%
Iovance Biotherapeutics Newsroom
Why Iovance Biotherapeutics (IOVA) Is Among the Best Low Priced Biotech Stocks to Buy Now
Need To Know: Analysts Just Made A Substantial Cut To Their Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Estimates
Truist Financial Maintains Iovance Biotherapeutics(IOVA.US) With Hold Rating, Maintains Target Price $5
Iovance Biotherapeutics Is Maintained at Outperform by Mizuho
Iovance Biotherapeutics Price Target Cut to $10.00/Share From $30.00 by Mizuho
Barclays Maintains Overweight on Iovance Biotherapeutics, Lowers Price Target to $4
Iovance Biotherapeutics Analyst Ratings
Truist Financial Downgrades Iovance Biotherapeutics(IOVA.US) to Hold Rating, Cuts Target Price to $5
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics First Quarter 2025 Earnings: Misses Expectations
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $20
Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $25
Mizuho Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $10
Iovance Biotherapeutics' Earnings Call: Mixed Sentiments and Future Prospects
U.S. Small Caps End Mixed As Regencell Bioscience Lead, Iovance Biotherapeutics Lags
Top Midday Decliners
12 Health Care Stocks Moving In Friday's Intraday Session
Iovance Biotherapeutics Stock Sinks Nearly 50% Intraday. Here's Why the Biotech Is Tumbling
Iovance Biotherapeutics Down Over 47%, On Track for Lowest Close Since June 2013 -- Data Talk
Iovance Biotherapeutics Cut to Market Perform From Market Outperform by JMP Securities